Times Square Capital Management, LLC Argenx Se Transaction History

Times Square Capital Management, LLC

$6.49 Billion
Q3 2024

A detailed history of Times Square Capital Management, LLC transactions in Argenx Se stock. As of the latest transaction made, Times Square Capital Management, LLC holds 109,490 shares of ARGX stock, worth $68.3 Million. This represents 0.91% of its overall portfolio holdings.

Number of Shares

109,490

Previous 100,650 8.78%

Holding current value

$68.3 Million

Previous $43.3 Million 37.19%

% of portfolio

0.91%

Previous 0.69%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	BUY	$434.22 - $551.9 $3.84 Million - $4.88 Million	8,840 Added 8.78%	109,490 $59.4 Million
Q2 2024 Aug 08, 2024	BUY	$356.01 - $451.55 $2.44 Million - $3.1 Million	6,860 Added 7.31%	100,650 $43.3 Million
Q1 2024 May 07, 2024	SELL	$356.95 - $413.29 $6.75 Million - $7.82 Million	-18,915 Reduced 16.78%	93,790 $36.9 Million
Q4 2023 Feb 07, 2024	BUY	$338.91 - $506.01 $3.71 Million - $5.54 Million	10,955 Added 10.77%	112,705 $42.9 Million
Q3 2023 Nov 17, 2023	BUY	$369.35 - $548.43 $4.09 Million - $6.07 Million	11,060 Added 12.2%	101,750 $50 Million
Q2 2023 Aug 09, 2023	SELL	$360.14 - $422.58 $905,752 - $1.06 Million	-2,515 Reduced 2.7%	90,690 $35.3 Million
Q1 2023 May 10, 2023	SELL	$334.23 - $403.65 $12.6 Million - $15.2 Million	-37,595 Reduced 28.74%	93,205 $34.7 Million
Q4 2022 Feb 10, 2023	SELL	$342.17 - $402.31 $863,979 - $1.02 Million	-2,525 Reduced 1.89%	130,800 $49.6 Million
Q3 2022 Nov 09, 2022	SELL	$343.2 - $395.75 $8.67 Million - $10 Million	-25,275 Reduced 15.94%	133,325 $47.1 Million
Q2 2022 Aug 05, 2022	SELL	$269.58 - $378.88 $4.04 Million - $5.68 Million	-15,000 Reduced 8.64%	158,600 $60.1 Million
Q1 2022 May 06, 2022	SELL	$254.45 - $351.06 $13.3 Million - $18.4 Million	-52,400 Reduced 23.19%	173,600 $54.7 Million
Q4 2021 Feb 04, 2022	BUY	$272.01 - $353.03 $6.64 Million - $8.61 Million	24,400 Added 12.1%	226,000 $79.1 Million
Q3 2021 Nov 08, 2021	SELL	$295.0 - $350.58 $5.16 Million - $6.14 Million	-17,500 Reduced 7.99%	201,600 $60.9 Million
Q2 2021 Aug 09, 2021	SELL	$257.11 - $319.92 $7.13 Million - $8.88 Million	-27,750 Reduced 11.24%	219,100 $66 Million
Q1 2021 May 12, 2021	BUY	$268.3 - $380.31 $57.9 Million - $82 Million	215,650 Added 691.19%	246,850 $68 Million
Q4 2020 Feb 12, 2021	SELL	$248.13 - $308.36 $3.1 Million - $3.85 Million	-12,500 Reduced 28.6%	31,200 $9.18 Million
Q3 2020 Nov 06, 2020	SELL	$215.51 - $272.51 $1.19 Million - $1.5 Million	-5,500 Reduced 11.18%	43,700 $11.5 Million
Q2 2020 Aug 07, 2020	SELL	$127.44 - $232.72 $9.39 Million - $17.2 Million	-73,695 Reduced 59.97%	49,200 $11.1 Million
Q1 2020 May 08, 2020	BUY	$108.83 - $165.23 $1.26 Million - $1.91 Million	11,560 Added 10.38%	122,895 $16.2 Million
Q4 2019 Feb 05, 2020	SELL	$106.59 - $164.21 $1.28 Million - $1.97 Million	-12,020 Reduced 9.74%	111,335 $17.9 Million
Q3 2019 Nov 05, 2019	SELL	$113.31 - $150.51 $45,324 - $60,204	-400 Reduced 0.32%	123,355 $14.1 Million
Q2 2019 Aug 02, 2019	BUY	$115.0 - $141.58 $69,000 - $84,948	600 Added 0.49%	123,755 $17.5 Million
Q1 2019 May 10, 2019	SELL	$98.85 - $134.59 $494,250 - $672,950	-5,000 Reduced 3.9%	123,155 $15.4 Million
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $1.13 Million - $1.94 Million	-17,700 Reduced 12.14%	128,155 $12.3 Million
Q3 2018 Nov 14, 2018	SELL	$75.5 - $96.63 $468,100 - $599,106	-6,200 Reduced 4.08%	145,855 $0
Q2 2018 Aug 14, 2018	SELL	$74.84 - $100.16 $860,660 - $1.15 Million	-11,500 Reduced 7.03%	152,055 $12.6 Million
Q1 2018 May 15, 2018	BUY	$56.95 - $85.19 $9.31 Million - $13.9 Million	163,555 New	163,555 $13.2 Million

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.5B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Times Square Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Times Square Capital Management, LLC with notifications on news.

Account

Times Square Capital Management, LLC Argenx Se Transaction History